{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:06:24Z","timestamp":1785305184226,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11938-018-0180-4","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T04:33:00Z","timestamp":1521779580000},"page":"226-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis"],"prefix":"10.1007","volume":"16","author":[{"given":"Carlos","family":"Moctezuma-Vel\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo J.","family":"Montano-Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"180_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11901-016-0287-9","volume":"15","author":"L Cabrera","year":"2016","unstructured":"Cabrera L, Abraldes J. Statins: The panacea of cirrhosis? Curr Hepatol Rep. 2016;15:1\u20137.","journal-title":"Curr Hepatol Rep"},{"issue":"2","key":"180_CR2","doi-asserted-by":"publisher","first-page":"G147","DOI":"10.1152\/ajpgi.00462.2007","volume":"296","author":"M Moreno","year":"2009","unstructured":"Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, Abraldes JG, et al. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol. 2009;296(2):G147\u201356.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"9","key":"180_CR3","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/gutjnl-2014-308338","volume":"64","author":"G Marrone","year":"2015","unstructured":"Marrone G, Maeso-Diaz R, Garcia-Cardena G, Abraldes JG, Garcia-Pagan JC, Bosch J, et al. KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. Gut. 2015;64(9):1434\u201343.","journal-title":"Gut"},{"issue":"3","key":"180_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","volume":"53","author":"J Bosch","year":"2010","unstructured":"Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53(3):558\u201367.","journal-title":"J Hepatol"},{"issue":"6","key":"180_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2007.01.020","volume":"46","author":"JG Abraldes","year":"2007","unstructured":"Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan JC, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol. 2007;46(6):1040\u20136.","journal-title":"J Hepatol"},{"issue":"5","key":"180_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"\u2022\u2022 Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150(5):1160\u201370 e3. Prospective study that showed a lower mortality in patients that received statins.","journal-title":"Gastroenterology"},{"issue":"3","key":"180_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126(3):749\u201355.","journal-title":"Gastroenterology"},{"issue":"5","key":"180_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651\u20138.","journal-title":"Gastroenterology"},{"issue":"11","key":"180_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"P Pollo-Flores","year":"2015","unstructured":"Pollo-Flores P, Soldan M, Santos UC, Kunz DG, Mattos DE, da Silva AC, et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis. 2015;47(11):957\u201363.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"180_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","volume":"9","author":"ZA Wani","year":"2017","unstructured":"Wani ZA, Mohapatra S, Khan AA, Mohapatra A, Yatoo GN. Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension. World J Hepatol. 2017;9(5):270\u20137.","journal-title":"World J Hepatol"},{"issue":"3","key":"180_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","volume":"42","author":"M Puppo Del","year":"2001","unstructured":"Del Puppo M, Galli Kienle M, Crosignani A, Petroni ML, Amati B, Zuin M, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res. 2001;42(3):437\u201341.","journal-title":"J Lipid Res"},{"issue":"5","key":"180_CR12","first-page":"890","volume":"15","author":"T Kurihara","year":"1993","unstructured":"Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther. 1993;15(5):890\u20138.","journal-title":"Clin Ther"},{"issue":"4","key":"180_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","volume":"36","author":"U Ritzel","year":"2002","unstructured":"Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol. 2002;36(4):454\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"180_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2009.08.052","volume":"209","author":"T Stojakovic","year":"2010","unstructured":"Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis. 2010;209(1):178\u201383.","journal-title":"Atherosclerosis"},{"issue":"3","key":"180_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/hep.21741","volume":"46","author":"T Stojakovic","year":"2007","unstructured":"Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007;46(3):776\u201384.","journal-title":"Hepatology"},{"key":"180_CR16","doi-asserted-by":"publisher","first-page":"CD008623","DOI":"10.1002\/14651858.CD008623.pub2","volume":"12","author":"L Eslami","year":"2013","unstructured":"Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;12:CD008623. https:\/\/doi.org\/10.1002\/14651858.CD008623.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"180_CR17","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","volume":"21","author":"K Kargiotis","year":"2015","unstructured":"\u2022\u2022 Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21(25):7860\u20138. This article shows that further investigation is needed regarding the role of statins in the treatment of NAFLD.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"180_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon TG, Bonilla H, Yan P, Chung RT, Butt AA. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology. 2016;64(1):47\u201357.","journal-title":"Hepatology"},{"issue":"2","key":"180_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2016","unstructured":"\u2022\u2022 Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis c-related compensated cirrhosis. Gastroenterology. 2016;150(2):430\u201340 e1. One of the largest observational studies showing a benefit of statins in patients with cirrhosis.","journal-title":"Gastroenterology"},{"issue":"3","key":"180_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/hep.23787","volume":"52","author":"SA Harrison","year":"2010","unstructured":"Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864\u201374.","journal-title":"Hepatology"},{"issue":"1","key":"180_CR21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1665-2681(19)30800-2","volume":"14","author":"C Manzano-Robleda Mdel","year":"2015","unstructured":"Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol. 2015;14(1):46\u201357.","journal-title":"Ann Hepatol"},{"key":"180_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66:896\u2013907.","journal-title":"Hepatology"},{"issue":"6","key":"180_CR23","doi-asserted-by":"publisher","first-page":"e462","DOI":"10.1097\/MD.0000000000000462","volume":"94","author":"CI Chen","year":"2015","unstructured":"Chen CI, Kuan CF, Fang YA, Liu SH, Liu JC, Wu LL, et al. Cancer risk in HBV patients with statin and metformin use: a population-based cohort study. Medicine (Baltimore). 2015;94(6):e462.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"180_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","volume":"63","author":"JC Hsiang","year":"2015","unstructured":"Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J Hepatol. 2015;63(5):1190\u20137.","journal-title":"J Hepatol"},{"issue":"7","key":"180_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ajg.2016.179","volume":"111","author":"YW Huang","year":"2016","unstructured":"Huang YW, Lee CL, Yang SS, Fu SC, Chen YY, Wang TC, et al. Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am J Gastroenterol. 2016;111(7):976\u201385.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"180_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/hep.27835","volume":"62","author":"AA Butt","year":"2015","unstructured":"Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015;62(2):365\u201374.","journal-title":"Hepatology"},{"issue":"6","key":"180_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s10654-013-9806-y","volume":"28","author":"SW Lai","year":"2013","unstructured":"Lai SW, Liao KF, Lai HC, Muo CH, Sung FC, Chen PC. Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol. 2013;28(6):485\u201392.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"180_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","volume":"144","author":"S Singh","year":"2013","unstructured":"Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323\u201332.","journal-title":"Gastroenterology"},{"issue":"6","key":"180_CR29","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jhep.2014.01.019","volume":"60","author":"A Drolz","year":"2014","unstructured":"Drolz A, Horvatits T, Michl B, Roedl K, Schellongowski P, Holzinger U, et al. Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. J Hepatol. 2014;60(6):1187\u201393.","journal-title":"J Hepatol"},{"issue":"8","key":"180_CR30","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","volume":"59","author":"S Kumar","year":"2014","unstructured":"Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014;59(8):1958\u201365.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"180_CR31","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/apt.12430","volume":"38","author":"C Motzkus-Feagans","year":"2013","unstructured":"Motzkus-Feagans C, Pakyz AL, Ratliff SM, Bajaj JS, Lapane KL. Statin use and infections in veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"180_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/0975-7406.171699","volume":"8","author":"J Jose","year":"2016","unstructured":"\u2022\u2022 Jose J. Statins and its hepatic effects: newer data, implications, and changing recommendations. J Pharm Bioallied Sci. 2016;8(1):23\u20138. Complete review mainly focused on the safety of statins from the liver perspective","journal-title":"J Pharm Bioallied Sci"},{"issue":"6","key":"180_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archinte.158.6.577","volume":"158","author":"DM Black","year":"1998","unstructured":"Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998;158(6):577\u201384.","journal-title":"Arch Intern Med"},{"issue":"2","key":"180_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.27157","volume":"60","author":"MW Russo","year":"2014","unstructured":"Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60(2):679\u201386.","journal-title":"Hepatology"},{"issue":"6","key":"180_CR35","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1002\/hep.23937","volume":"52","author":"A Reuben","year":"2010","unstructured":"Reuben A, Koch DG, Lee WM. Acute Liver Failure Study G. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065\u201376. https:\/\/doi.org\/10.1002\/hep.23937.","journal-title":"Hepatology"},{"issue":"2","key":"180_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/liv.13308","volume":"37","author":"ES Bjornsson","year":"2017","unstructured":"Bjornsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int. 2017;37(2):173\u20138.","journal-title":"Liver Int"},{"issue":"8","key":"180_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","volume":"40","author":"V Alla","year":"2006","unstructured":"Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006;40(8):757\u201361.","journal-title":"J Clin Gastroenterol"},{"key":"180_CR38","unstructured":"http:\/\/livertox.nih.gov\/.Accessed September 23, 2017."},{"issue":"5","key":"180_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287\u201392.","journal-title":"Gastroenterology"},{"issue":"5","key":"180_CR40","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"JH Lewis","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46(5):1453\u201363.","journal-title":"Hepatology"},{"issue":"4","key":"180_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1592\/phco.28.4.522","volume":"28","author":"MD Onofrei","year":"2008","unstructured":"Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy. 2008;28(4):522\u20139.","journal-title":"Pharmacotherapy"},{"issue":"3 Suppl","key":"180_CR42","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","volume":"8","author":"H Bays","year":"2014","unstructured":"\u2022\u2022 Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association\u2019s Statin Safety Task F. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47\u201357. Specific recommendations of a panel of experts about the liver safety of statins; the strength of the recommendations and quality of evidence are given.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"180_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4065\/mcp.2009.0365","volume":"85","author":"RM Calderon","year":"2010","unstructured":"Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85(4):349\u201356.","journal-title":"Mayo Clin Proc"},{"issue":"Suppl 1","key":"180_CR44","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1111\/j.1530-0277.2012.01901.x","volume":"37","author":"D Theile","year":"2013","unstructured":"Theile D, Haefeli WE, Seitz HK, Millonig G, Weiss J, Mueller S. Association of liver stiffness with hepatic expression of pharmacokinetically important genes in alcoholic liver disease. Alcohol Clin Exp Res. 2013;37(Suppl 1):E17\u201322.","journal-title":"Alcohol Clin Exp Res"},{"issue":"Suppl 1","key":"180_CR45","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/S0168-8278(02)00430-0","volume":"38","author":"J Bosch","year":"2003","unstructured":"Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38(Suppl 1):S54\u201368.","journal-title":"J Hepatol"},{"issue":"1","key":"180_CR46","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242\u201353.","journal-title":"Hepatology"},{"issue":"6","key":"180_CR47","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jhep.2007.01.021","volume":"46","author":"G Targher","year":"2007","unstructured":"Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol. 2007;46(6):1126\u201332.","journal-title":"J Hepatol"},{"issue":"1","key":"180_CR48","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/ajg.2012.362","volume":"108","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti A, Erice E, Gilabert R, Reverter E, Abraldes JG, Garcia-Pagan JC, et al. Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. Am J Gastroenterol. 2013;108(1):75\u201382.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"180_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51(2):265\u20139.","journal-title":"Gut"},{"issue":"2","key":"180_CR50","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","volume":"194","author":"A Sorokin","year":"2007","unstructured":"Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194(2):293\u20139.","journal-title":"Atherosclerosis"},{"issue":"5","key":"180_CR51","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/nu5051544","volume":"5","author":"M Gaggini","year":"2013","unstructured":"Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544\u201360.","journal-title":"Nutrients"},{"issue":"1","key":"180_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tem.2009.07.005","volume":"21","author":"GH Syed","year":"2010","unstructured":"Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010;21(1):33\u201340.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"180_CR53","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrgastro.2015.78","volume":"12","author":"J Bosch","year":"2015","unstructured":"Bosch J, Forns X. Therapy Statins and liver disease: from concern to \u2018wonder\u2019 drugs? Nat Rev Gastroenterol Hepatol. 2015;12(6):320\u20131.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"180_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.21232","volume":"44","author":"M Ikeda","year":"2006","unstructured":"Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44(1):117\u201325.","journal-title":"Hepatology"},{"issue":"5","key":"180_CR55","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/liv.12316","volume":"34","author":"DA Sheridan","year":"2014","unstructured":"Sheridan DA, Bridge SH, Crossey MM, Felmlee DJ, Fenwick FI, Thomas HC, et al. Omega-3 fatty acids and\/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy\u2014a pilot randomised clinical trial. Liver Int. 2014;34(5):737\u201347.","journal-title":"Liver Int"},{"issue":"1","key":"180_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jhep.2014.08.013","volume":"62","author":"TG Simon","year":"2015","unstructured":"Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62(1):18\u201323.","journal-title":"J Hepatol"},{"issue":"3","key":"180_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.antiviral.2010.02.325","volume":"86","author":"T Bader","year":"2010","unstructured":"Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antivir Res. 2010;86(3):241\u20135.","journal-title":"Antivir Res"},{"issue":"6","key":"180_CR58","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.2011.36.0917","volume":"30","author":"YT Tsan","year":"2012","unstructured":"Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol. 2012;30(6):623\u201330.","journal-title":"J Clin Oncol"},{"key":"180_CR59","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"\u2022\u2022 Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1521\u201330. Meta-analysis that reinforces the concept that statins may probably decrease mortality in patients with cirrhosis.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5519","key":"180_CR60","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160\u20134.","journal-title":"Science"},{"issue":"3","key":"180_CR61","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep.26127","volume":"57","author":"V Mura La","year":"2013","unstructured":"La Mura V, Pasarin M, Meireles CZ, Miquel R, Rodriguez-Vilarrupla A, Hide D, et al. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. Hepatology. 2013;57(3):1172\u201381.","journal-title":"Hepatology"},{"issue":"6","key":"180_CR62","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jhep.2013.02.005","volume":"58","author":"J Gracia-Sancho","year":"2013","unstructured":"Gracia-Sancho J, Garcia-Caldero H, Hide D, Marrone G, Guixe-Muntet S, Peralta C, et al. Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. J Hepatol. 2013;58(6):1140\u20136.","journal-title":"J Hepatol"},{"issue":"6","key":"180_CR63","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1042\/CS20140622","volume":"129","author":"CC Chang","year":"2015","unstructured":"Chang CC, Wang SS, Hsieh HG, Lee WS, Chuang CL, Lin HC, et al. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung. Clin Sci (Lond). 2015;129(6):449\u201360.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"180_CR64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/SHK.0b013e3181cd8d05","volume":"34","author":"B Relja","year":"2010","unstructured":"Relja B, Lehnert M, Seyboth K, Bormann F, Hohn C, Czerny C, et al. Simvastatin reduces mortality and hepatic injury after hemorrhage\/resuscitation in rats. Shock. 2010;34(1):46\u201354.","journal-title":"Shock"},{"issue":"3","key":"180_CR65","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/SHK.0000000000000734","volume":"47","author":"CZ Meireles","year":"2017","unstructured":"Meireles CZ, Pasarin M, Lozano JJ, Garcia-Caldero H, Gracia-Sancho J, Garcia-Pagan JC, et al. Simvastatin attenuates liver injury in rodents with biliary cirrhosis submitted to hemorrhage\/resuscitation. Shock. 2017;47(3):370\u20137.","journal-title":"Shock"},{"issue":"4","key":"180_CR66","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","volume":"53","author":"J Trebicka","year":"2010","unstructured":"Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol. 2010;53(4):702\u201312.","journal-title":"J Hepatol"},{"issue":"1","key":"180_CR67","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/hep.28537","volume":"64","author":"JG Abraldes","year":"2016","unstructured":"Abraldes JG, Burak KW. STAT order: should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma? Hepatology. 2016;64(1):13\u20135.","journal-title":"Hepatology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-018-0180-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-018-0180-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T19:49:06Z","timestamp":1660679346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-018-0180-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1007\/s11938-018-0180-4","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"23 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Carlos Moctezuma-Vel\u00e1zquez declares that he has no conflict of interest. Juan Abraldes declares that he has no conflict of interest. Aldo Montano-Loza declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}